Rosuvastatin (20–40 mg): high intensity. Observational study performed in 253 patients with malignant pleural mesothelioma or advanced NSCLC treated with PD-1 inhibitors. This evidence concerns the gene PDCD1 and malignant pleural mesothelioma.